Table 2 Treatment-related adverse events (n = 44)

From: Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study

Adverse events

Any grade n (%)

Grade 3–4 n (%)

Any grade

43 (97.7)

12 (27.3)

Anemia

41 (93.2)

1 (2.3)

Fatigue

25 (56.8)

0 (0.0)

Decreased appetite

23 (52.3)

0 (0.0)

Constipation

23 (52.3)

0 (0.0)

Nausea

21 (47.7)

0 (0.0)

Neutrophil count decreased

20 (45.5)

7 (15.9)

Diarrhea

20 (45.5)

0 (0.0)

ALT increased

18 (40.9)

0 (0.0)

AST increased

18 (40.9)

0 (0.0)

Platelet count decreased

17 (38.6)

3 (6.8)

Proteinuria

17 (38.6)

1 (2.3)

Bilirubin increased

14 (31.8)

0 (0.0)

Creatinine increased

13 (29.5)

1 (2.3)

White cell count decreased

12 (27.3)

6 (13.6)

Vomiting

12 (27.3)

0 (0.0)

GGT increased

10 (22.7)

0 (0.0)

Hyperglycemia

9 (20.5)

0 (0.0)

LDH increased

9 (20.5)

0 (0.0)

Hematuria

8 (18.2)

0 (0.0)

ALP increased

8 (18.2)

0 (0.0)

Hypokalemia

8 (18.2)

0 (0.0)

  1. Data cutoff: April 1, 2024
  2. Data are number of patients (% of patients)
  3. TRAEs with an incidence of ≥10% of patients are reported
  4. AEs were graded based on CTCAE version 5.0
  5. ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl transpeptidase, LDH lactate dehydrogenase, ALP alkaline phosphatase
Back to article page